Last edition
News about "ALTITUDE-AD "
Acumen Pharma Presents New Data on pTau217 Assay at Annual CTAD Conference
The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen’s Phase 1 INTERCEPT-AD trial, which did not use this approach.
ALTITUDE-AD | 01/11/2024 | By Aishwarya
Acumen Announces First Patient Dosed in ALTITUDE-AD
Acumen Pharmaceuticals, Inc. has announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
ALTITUDE-AD | 08/05/2024 | By Aishwarya | 126
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy